Oncology & Cancer

SABCS: no benefit in extending trastuzumab in HER2 breast CA

(HealthDay)—For patients with human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer, one year of adjuvant trastuzumab should remain the standard of care, according to a study presented at the ...

Oncology & Cancer

Researchers identify gene involved in lung tumor growth

Lung cancer researchers at St. Joseph's Hospital and Medical Center in Phoenix, Ariz., in collaboration with researchers at the Translational Genomics Research Institute and other institutions, have identified a gene that ...

page 13 from 18